

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TL300879

Tropomyosin 3 (TPM3) Human shRNA Plasmid Kit (Locus ID 7170)

Product data:

Product Type:	shRNA Plasmids
Product Name:	Tropomyosin 3 (TPM3) Human shRNA Plasmid Kit (Locus ID 7170)
Locus ID:	7170
Synonyms:	CAPM1; CFTD; HEL-189; HEL-S-82p; hscp30; NEM1; OK/SW-cl.5; TM-5; TM3; TM5; TM30; TM30nm; TPM3nu; TPMsk3; TRK
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	TPM3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 7170). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM 001043351, NM 001043352, NM 001043353, NM 001278188, NM 001278189, NM 001278190, NM 001278191, NM 152263, NM 153649, NR 103460, NR 103461, NM 001349679, NM 152263.1, NM 152263.2, NM 152263.3, NM 153649.1, NM 153649.2, NM 153649.3, NM 001043351.1, NM 001043353.1, NM 001043352.1, NM 001278191.1, NM 001278188.1, NM 001278190.1, NM 001278189.1, BC008425, BC008425.1, BC072428, BC072428.1, BC000771, BC008407, BC015403, BC017195, BC050470, BC062740, BC073144, BM674269, BM674651, NM 001364679, NM 001364681, NM 001364683, NM 001364680, NM 001364682, NM 001278189.2, NM 153649.4, NM 001043352.2, NM 001278188.2, NM 001278191.2, NM 001043353.2, NM 001043351.2, NM 152263.4
UniProt ID:	<u>P06753</u>



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

	Tropomyosin 3 (TPM3) Human shRNA Plasmid Kit (Locus ID 7170) – TL300879
Summary:	This gene encodes a member of the tropomyosin family of actin-binding proteins. Tropomyosins are dimers of coiled-coil proteins that provide stability to actin filaments and regulate access of other actin-binding proteins. Mutations in this gene result in autosomal dominant nemaline myopathy and other muscle disorders. This locus is involved in translocations with other loci, including anaplastic lymphoma receptor tyrosine kinase (ALK) and neurotrophic tyrosine kinase receptor type 1 (NTRK1), which result in the formation of fusion proteins that act as oncogenes. There are numerous pseudogenes for this gene on different chromosomes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .
Performance Guaranteed:	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
	For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US